These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3241755)

  • 1. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of auditory function in homozygous beta-thalassemia].
    Stura M; Arigliani R; Molinari AC; Tarantino V
    Pediatr Med Chir; 1986; 8(5):703-5. PubMed ID: 3601700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term audiological evaluation of beta-thalassemic patients.
    Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
    Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G; Koussi A; Tsatra J; Noussios G; Vital V; Sagarakis G; Athanassiou M
    Int J Pediatr Otorhinolaryngol; 1996 May; 35(3):223-30. PubMed ID: 8762595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M; Meleleo D; Tricarico N; Greco Miani A; Serra E; Parlatore L
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can deferoxamine be considered an ototoxic drug?
    Masala W; Meloni F; Gallisai D; Careddu M; Secchi G; Cuccuru GB; Loriga V; Salvo G
    Scand Audiol Suppl; 1988; 30():237-8. PubMed ID: 3227279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment.
    Ambrosetti U; Dondè E; Piatti G; Cappellini MD
    Pharmacol Res; 2000 Nov; 42(5):485-7. PubMed ID: 11023713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.
    Chao YH; Wu KH; Lin CY; Tsai MH; Peng CT; Wu HP; Lin CD
    Pediatr Blood Cancer; 2013 Dec; 60(12):1963-6. PubMed ID: 23956204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audiologic results in patients with Moebiüs sequence.
    Griz S; Cabral M; Azevedo G; Ventura L
    Int J Pediatr Otorhinolaryngol; 2007 Sep; 71(9):1457-63. PubMed ID: 17640740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ototoxicity of deferoxamine].
    de España R; Biurrun O; Lorente J; Valls J; Orteu N; Traserra J
    An Otorrinolaringol Ibero Am; 1992; 19(4):341-7. PubMed ID: 1636908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions.
    Olivieri NF; Buncic JR; Chew E; Gallant T; Harrison RV; Keenan N; Logan W; Mitchell D; Ricci G; Skarf B
    N Engl J Med; 1986 Apr; 314(14):869-73. PubMed ID: 3485251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The echocardiography in thalassemia major (author's transl)].
    Musumeci S; Schiliro G; Romeo MA; Di Gregorio F; Russo G; Scibilia G
    Pediatr Med Chir; 1981; 3(2-3):219-22. PubMed ID: 6211659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Barratt PS; Toogood IR
    Med J Aust; 1987 Aug; 147(4):177-9. PubMed ID: 3657630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
    Karimi M; Asadi-Pooya AA; Khademi B; Asadi-Pooya K; Yarmohammadi H
    Acta Haematol; 2002; 108(2):79-83. PubMed ID: 12187025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.
    Wonke B; Hoffbrand AV; Aldouri M; Wickens D; Flynn D; Stearns M; Warner P
    Arch Dis Child; 1989 Jan; 64(1):77-82. PubMed ID: 2923478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients.
    Chen SH; Liang DC; Lin HC; Cheng SY; Chen LJ; Liu HC
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):651-3. PubMed ID: 16344669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.